Neurocrine biosciences reports third quarter 2023 financial results and raises 2023 ingrezza sales guidance
Ingrezza® (valbenazine) third quarter net product sales of $486 million representing 29% year-over-year growth ingrezza® (valbenazine) 2023 net product sales guidance raised to $1.82 - $1.84 billion crinecerfont adult and pediatric cahtalysttm studies met primary endpoint and key secondary endpoints for the treatment of congenital adrenal hyperplasia analyst day on december 5th focused on r&d portfolio and strategy san diego , oct. 31, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the third quarter ended september 30, 2023, raised 2023 net sales guidance for ingrezza, and announced an analyst day to be held in new york city on december 5th. "with ingrezza sales continuing to grow, an expanded indication to treat chorea associated with huntington's disease, and positive phase 3 results in congenital adrenal hyperplasia, neurocrine remains well positioned to build a leading neuroscience-focused company," said kevin gorman, ph.d.
NBIX Ratings Summary
NBIX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission